Instructions to authors

Contents

Scope of the journal

The American Journal of Clinical Pathology (AJCP) publishes high-quality scientific articles and reviews that are directly applicable to the practice of pathology and laboratory medicine across all clinical settings.  This includes investigation of laboratory tests, methods, algorithms, and conceptual frameworks for diagnosis, prognostication, and management in all subspecialty areas of anatomic and clinical pathology. AJCP additionally publishes descriptive case series that add new knowledge or insights into the pathology of specific diseases.  Also in scope are manuscripts in the areas of quality improvement, laboratory management, test utilization/stewardship, education and training, and global health.

Out of scope are basic or early translational studies without near-term applicability to practice, case reports that don’t add significant new knowledge to the understanding of disease, and purely clinical studies that utilize routinely available laboratory tests.

How we publish

American Journal of Clinical Pathology is a peer-reviewed journal publishing two (2) volumes of six (6) issues per year online.

After copyediting and review of the final proof, papers are published into the currently open issue.

The Version of Record requires a correction notice for any changes after it is published, even if it is not yet placed in an issue. See the definitions of the Version of Record and other versions of the paper for more details.

Submitting

American Journal of Clinical Pathology (AJCP) a leading international journal for publication of articles concerning novel anatomic pathology and laboratory medicine observations on human disease. We appreciate your interest in submitting your manuscript to AJCP and look forward to the opportunity to consider it.

AJCP is an official publication of the American Society for Clinical Pathology (ASCP). To publish the Journal, ASCP partners with Oxford University Press (OUP), a not-for-profit publisher and a department of the University of Oxford. Learn more about how publishing with OUP reinvests in the scholarly community on the OUP for Authors page.

After preparing your manuscript according to the guidance in the Preparing your manuscript section, you can submit your work through the through the Journal’s online submission site. If you have not used our submission site before, you will need to create an account. Additional help and instructions are available on the submissions site as you go through the submission process. Please contact us with any questions about submitting your manuscript.

Manuscript submission guide

Article types

All articles are peer reviewed unless otherwise indicated. The Journal publishes several different article types:

Original Article

AJCP is devoted to prompt publication of original studies and observations in clinical and anatomic pathology. Original papers relating to laboratory use, management, education, and information science will be considered. AJCP limits publication of case reports to those that provide novel observations related to disease classification or biology.

Each submission should include:

  • Anonymized main manuscript file:
    • Structured abstract—maximum word count: 250
      • Abstract headers: Objectives, Methods, Results, Conclusions
    • Keywords— minimum of 3 and maximum of 10
    • Key points – 3 required key points
    • Text—maximum word count: no limit
    • May include tables and figures—no limit
  • Title page to facilitate double-anonymized peer review:
    • Must include:
      • Conflict of interest statement
      • Funding disclosure
      • Data availability statement
    • May include:
      • Author contributions (with CRediT details)
      • Acknowledgments (incl. AI disclosure)
      • Human and animal experiment disclosures, where relevant
  • References— no limit

Review Article

AJCP publishes review articles dealing with practical topics in clinical and anatomic pathology. Although many of these are solicited by the editorial board, unsolicited submissions are welcome. Comments are welcome from the readership regarding potential topics for review. All review articles are subject to peer review before publication.

Each submission should include:

  • Anonymized main manuscript file:
    • Structured abstract—maximum word count: 250
      • Abstract headers: Objectives, Methods, Results, Conclusions
    • Keywords— minimum of 3 and maximum of 10
    • Key points – 3 required key points
    • Text—maximum word count: 6,000
    • May include tables and figures—no limit
  • Title page to facilitate double-anonymized peer review:
    • Must include:
      • Conflict of interest statement
      • Funding disclosure
      • Data availability statement
    • May include:
      • Author contributions (with CRediT details)
      • Acknowledgments (incl. AI disclosure)
      • Human and animal experiment disclosures, where relevant
  • References— max. 50 references

Special Article

AJCP welcomes articles that are of interest to the journal’s readership but that do not fall under the journal’s other categories of submission. Examples include white papers and special reports.

Each submission should include:

  • Anonymized main manuscript file:
    • Structured abstract—maximum word count: 250
      • Abstract headers: Objectives, Methods, Results, Conclusions
      • If you believe that a structured abstract is inappropriate for your special article submission, please contact the editorial office.
    • Keywords— minimum of 3 and maximum of 10
    • Key points – 3 required key points
    • Text—maximum word count: no limit
    • May include tables and figures—no limit
  • Title page to facilitate double-anonymized peer review:
    • Must include:
      • Conflict of interest statement
      • Funding disclosure
      • Data availability statement
    • May include:
      • Author contributions (with CRediT details)
      • Acknowledgments (incl. AI disclosure)
      • Human and animal experiment disclosures, where relevant
  • References— no limit

Brief Report

Brief Reports are short manuscripts documenting informative clinical observations. Submissions to this category will not be considered unless they elucidate novel and important findings; Brief Reports are not intended to allow publication of incomplete or preliminary findings. The peer review process is as equally rigorous as for other articles.

Each submission should include:

  • Anonymized main manuscript file:
    • Structured abstract—maximum word count: 250
      • Abstract headers: Objectives, Methods, Results, Conclusion
    • Keywords— minimum of 3 and maximum of 10
    • Key points – 3 required key points
    • Text—maximum word count: 1,500
    • May include tables and figures—max. 2 figures and/or tables
  • Title page to facilitate double-anonymized peer review:
    • Must include:
      • Conflict of interest statement
      • Funding disclosure
      • Data availability statement
    • May include:
      • Author contributions (with CRediT details)
      • Acknowledgments (incl. AI disclosure)
      • Human and animal experiment disclosures, where relevant
  • References— max. 25 references

Letter to the Editor and Response to Letter to the Editor

The Journal welcomes Letters to the Editor from readers offering relevant comments and providing objective and scholarly criticism of recently published articles in the Journal. Contributions should be constructive, professional, and polite. The Journal will only consider submissions pertaining to articles published in the past two years. After the initial Letter to the Editor and Response to Letter to the Editor, no further submissions on the same topic will be considered.

At the discretion of the editors, Letters to the Editor being considered for publication may be sent to the authors of the original article to give them the opportunity to submit a Response to Letter to the Editor. If an author does not submit a Response to Letter to the Editor, the Journal may publish a statement indicating this to readers. To enable readers to evaluate the arguments presented, initial Letters to the Editor and Responses to Letters to the Editor are linked to the original article, are typically published online simultaneously, and may be published together in the same issue.

Submitted Letters to the Editor will undergo an initial assessment by the editors, at which point they may be rejected, sent for revision, or accepted. At the discretion of the editors, Letters to the Editor may be sent for peer review or may be considered without external peer review. Letters to the Editor on the same topic or in response to the same article may be grouped, sent to the corresponding author of the original article for reply, and published at the same time. Authors of Letters to the Editor and Responses to Letters to the Editor may be asked to complete authorship forms, disclose conflicts of interest, and sign publishing agreements (if accepted), as with any manuscript submitted or published in the Journal. The Journal may request revisions to Letters to the Editor and Responses to Letters to the Editor] for content, length, clarity, grammar, style, and format.

The Journal requires all titles for Letters to the Editor to be formatted by authors with the following layout: “Letter to the Editor regarding <ARTICLE TITLE BEING RESPONDED TO IN SENTENCE CASE>”.   

The Journal requires all titles for Responses to Letters to the Editor to be formatted by authors within the following layout: “Response to Letter to the Editor regarding <ARTICLE TITLE BEING RESPONDED TO IN SENTENCE CASE>”.   

Each submission should include:

  • Text—maximum word count: 500
  • May not include tables and figures
  • Must include the following back matter sections:
    • Acknowledgements
    • Conflicts of interest
    • AI disclosure
  • References— max. 5 references (one of which is the subject AJCP article)

Editorial

AJCP mainly publishes invited editorials but will consider freestanding editorials related to timely topics.

Each submission should include:

  • Text—maximum word count: 1,500
  • Keywords— minimum of 3 and maximum of 10
  • May include tables and figures—no limit
  • Must include the following back matter sections:
    • Acknowledgements
    • Conflicts of interest
    • AI disclosure
  • References— max. 5 references

Preparing your manuscript

General guidelines on preparing your manuscript for publication can be found on OUP’s Preparing and submitting a manuscript page. Specific instructions for American Journal of Clinical Pathology can be found below.

Pre-submission language editing

You may wish to use a language-editing service before submitting to ensure that editors and reviewers understand your manuscript. Our publisher, Oxford University Press, partners with Enago, a leading provider of author services. Through the OUP-Enago partner page, prospective authors are entitled to a discount for language editing, abstract and layperson summary writing, rejected manuscript editing, and creation of graphical abstracts, illustrations, and videos.

Enago is an independent service provider, which will handle all aspects of this service, including payment. As an author you are under no obligation to take up this offer. Language editing and other services from Enago are optional and do not guarantee that your manuscript will be accepted. Edited manuscripts will undergo the regular review process of the Journal. For more details and a list of additional resources, please see OUP’s page on language services.

Cover letter

Authors may include a cover letter with their submission. This letter represents an opportunity to explain the value of the work to the Editors. The use of AI (for example, to help generate content or images, write code, process data, or for translation) should be disclosed in the cover letter.

Title page

To ensure that authors receive a review that is as unbiased and fair as possible, AJCP uses double-anonymized review, which means that reviewer and author identities are concealed from each other throughout the review process. To aid in this, authors need to ensure that their manuscripts are prepared in a way that does not give away their identity. The title page should be submitted separately from the rest of the manuscript, and is the only document that should reveal the identity of the authors.  

The full title page should include: 

  • The title of the paper avoiding abbreviations
  • All full author names, author degrees, and affiliation addresses  
    • Full affiliation address elements include: Division/Department, Institution/Organization, Full Street/Road Address, City, State abbreviation/Region abbreviation/State name in full, Postal Code/Zip Code, and Country 
    • Dual lead and/or senior authorship should be indicated here. 
  • Full mailing address and contact information of one corresponding author 
    • Full corresponding mailing address elements include: Division/Department, Institution/Organization, Full Street/Road Address, City, State abbreviation/Region abbreviation/State name in full, Postal Code/Zip Code, and Country 
    • Full contact information includes: [full author name, highest-held academic degree, telephone number, fax number, email address] 
  • Statements relating to ethical or integrity policies, which may include any of the following: 
    • Data availability statement 
      • The statement should describe and provide means of access, where possible, by linking to the data and/or code providing the required unique identifier. 
    • Conflicts of Interest section  
    • Author contributions (CRediT) 
    • AI disclosure
    • Funding/financial interest information section 
    • Authors should disclose the sources of any support for the work received in the form of grants and/or equipment and drugs. If no funding was received for the study, the authors should still include the section and state “None declared.”
    • Acknowledgments section 
    • These should be brief and should include any individuals who contributed to the research described in the paper or to the development of the manuscript but who do not fulfil the criteria to be listed as an author. 
    • Ethical approval statement (if applicable) 
    • Patient consent statement (if applicable) 
    • Clinical trial registration (if applicable) 
    • Permission to reproduce material from other sources (if applicable) 
  • Please also consider:
    • Figures and tables should not have any affiliation-related identifiers.
    • Identifying information, including author names and university/hospital names, should be eliminated from file names.
    • Document properties need to be anonymized.
    • The third person should be used to refer to work the authors have previously undertaken, e.g., replace any phrases like “as we have shown before [reference]” with “as has been shown before [reference].” It is not necessary to eliminate essential self-references.

Text abstracts

Text abstracts must be written in English and should be designed to summarise the essential features of the paper in a logical and concise sequence. The abstract should be included within the main manuscript file. 

Abstracts should be structured, have a maximum length of 250 words, and must not contain reference citations or abbreviations. Abstracts should include the following subheadings which should appear in the text of the abstract: 

  • Objectives 
  • Methods 
  • Results 
  • Conclusions 

Abstracts are required for all article types except Special Articles, Editorials, Letters to the Editor, and Responses to Letters to the Editor.

Keywords

Keywords, categorizing the article, should be added to aid discoverability as these will assist indexers in cross-indexing the article and may be published with the article. Please see the Article types section for keyword requirements for particular article types for the Journal.  

Authors choose from a list of keywords/classifications that is made available in the journal submission system but should avoid repeating words from the article title.

In the published article, keywords will be ordered as supplied by the author.

Key Points

AJCP asks authors to supply three key points for submissions. The key points should briefly provide a synopsis encapsulating the significance of the research and its implications for readers. Authors should consider these questions when formulating key points:

  • What issue or core problem does the study address?
  • What would one take-home point for the working medical professional be?
  • What is the most significant or most interesting finding of the study?

Key points will be published as part of the article and may also be used for social media promotion. Key points should be written in complete sentence format and should be no longer than 200 characters (including spaces).  Please include the key points as part of the main text document for submission.

Acknowledgments

Authors of all article types are encouraged to submit an “Acknowledgments” section, which should be set as a single paragraph, clearly marked with a separate heading, and included on the title page. 

Author names within this section should be given as closed initials with dots (C.J.D.). Do not include study funding or conflict of interest/disclosure information within this section, as that information should instead be included within the Funding or Conflicts of interest sections. 

Acknowledgments may consist of: a list of participants, investigators, or study groups within a group study; mention of previous presentations of the material; preprint information; additional contributions or thanks; contributions to the paper that do not qualify for authorship (see Authorship section for additional detail); deceased author details; and/or miscellaneous acknowledgments. 

The use of AI (for example, to help generate content or images, write code, process data, or for translation) should be disclosed in Acknowledgments (as well as cover letter and Methods section).

Funding

Authors of all article types except Editorials and Letters to the Editor/Responses to Letter to the Editor are required to submit a “Funding” section that is clearly marked with a separate heading and included on the title page. 

Authors must fully declare all funding information relevant to the study, including specific grant numbers.

The following rules should be followed:

  • The sentence should begin: ‘This work was supported by …’
  • The full official funding agency name should be given, ie, ‘National Institutes of Health’, not ‘NIH’ (full RIN-approved list of UK funding agencies) Grant numbers should be given in parentheses.
  • Multiple grant numbers should be separated by a comma.
  • Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency).
  • Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.

An example is given here: ‘This work was supported by the National Institutes of Health (grant AA123456 to C.S., grant BB765432 to M.H.); and the Alcohol & Education Research Council (grant hfygr667789).’

Oxford University Press will deposit all NIH-funded articles in PubMed Central. See the NIH webpage for details. Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines above.

If the funder is listed in the Crossref Open Funder Registry, the funder name should be included exactly as it appears within that database. Where grants were received by specific members of the author group, the authors should be identified using closed initials with dots (C.J.D.). If no funding was received for the study, the authors should still include the section and state “None declared.”

Conflicts of interest

Authors of all article types are required to submit a “Conflicts of interest” section that is clearly marked with a separate heading and included on the title page. For more information, please refer to OUP’s definition of conflicts of interest and the Authors’ section of the potential conflicts of interest section. 

Any listed authors in this section should be identified using closed initials with dots (C.J.D.). If there are no conflicts of interest to disclose, the authors should still include the section and state “None declared.” 

Style

The journal follows AMA 11 style. Please refer to these requirements when preparing your manuscript. More information on the style guide is available. US spelling should be used throughout, except in quotations and in references.

Text

The introduction should state clearly the purpose and rationale of the study being presented. In Methods, established techniques may be referenced; however, new or modified methods should be described in sufficient detail to allow duplication of the study by an independent observer. Describe Results concisely and logically. The Discussion should emphasize novel or significant aspects of the study. Conclusions should not be based on unpublished observations or data derived solely from the previous literature.

Nomenclature

Use current editions of Dorland's Medical Dictionary given in Bergey's Manual of Determinative Bacteriology. Identify all drugs by both their generic and trade names and Webster's International Dictionary as references. Use the nomenclature of bacteria, and chemicals by generic name, followed in parentheses by the chemical formula when deemed appropriate. The TNM method for staging tumors is required (see American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer-Verlag; 2017).

To conduct a search for preferred, internationally accepted terms and definitions, refer to the Clinical and Laboratory Standards Institute (CLSI) Harmonized Terminology Database.

Gene Terminology

Symbols denoting nucleic acid products (genes, alleles, mRNAs, etc) should be italicized; symbols denoting amino acid products (proteins) should be represented in standard fonts.

Abbreviations

Use standard abbreviations whenever possible (see Council for Biology Editors. Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers. 6th ed. New York, NY: Cambridge University Press; 1994). The full term for which the abbreviation stands, followed by the abbreviation in parentheses, should precede the first use of the abbreviation in the abstract, text, tables, and figure legends, except for standard units of measurement.

Units

All quantitative measurements must be expressed in conventional metric units, followed in parentheses by SI units. pH, gas pressure measurements (eg, PO2 and Pco2), and osmolality should be reported in conventional units only. Express temperature in degrees Celsius. Express enzyme activity in international units per liter (IU/L). Base all SI concentration units on a volume of 1 L. Express as amount of substance (mole) or mass (gram) units, with the appropriate prefix (eg, milli- [m] or micro- [µ]). In describing reagent preparations, give weights and volumes in conventional metric units only (eg, Stock 500 mmol/L glucose standard; add 0.900 g of glucose to 10 mL of water in a 100-mL volumetric flask, dissolve, and fill to the mark with water).

Laboratory methods and specimen handling

Follow these requirements for clinical studies that include laboratory testing for biomarkers:

  • For commercial diagnostic tests, authors must include the actual name and generation of assay, the manufacturer, and the instrument used for analyses.
  • Authors must report performance characteristics, such as the imprecision of the assay in the investigators’ laboratories, the assay’s reportable range, and any reference (normal) range used in the study.
  • Authors must clearly indicate the types of specimens analyzed and the storage conditions for these specimens.

The rationale for these requirements is provided in a downloadable pdf.

Biostatistics

AJCP authors should adhere to the SAMPL statistical guidelines when performing statistical analysis of their work. 

Tables

Tables should present new information rather than duplicating what is in the text. Readers should be able to interpret the table without reference to the text. 

Authors must number all tables (e.g., Table 1, Table 2, Table 3) and must mention them within the text in chronological order. Tables should be supplied in an editable format (preferably Microsoft Word), and not embedded as an image or as a spreadsheet file. All tables should include a caption or title explaining the contents. Authors should place tables within the main text close to where they are first referenced.

Do not use color and shading (which cannot be replicated in the online version for accessibility reasons) or spacing/tabbed spacing to indicate alignment. Ensure that any formatting, symbols, or abbreviations are explained in the table footnote, even if previously defined in the main text. Provide units in column or row headers, rather than in the table body, unless the row/column features mixed units.

Figures

All figures and their captions should be embedded in the text in the correct numerical order to facilitate reviewing.  At a later stage, you will be required to submit figures as individual files. Figures should be submitted in one of the following file formats: .jpeg, .jpg, .png, .tiff, or .eps (see specifics below). Images prepared as .bmp, .gif, or .doc/.docx files will not be accepted. Please see OUP's guidance on appropriate file format and resolution for graphics. Figures should be clearly named to match their citation in the manuscript, e.g. fig1.tiff, fig2.eps. When sizing your images, please consider the overall page dimensions and layout and the final reduction necessary for publication. 

Figure titles, legends and captions should be included within the manuscript file, not in the image files. Captions should include definitions of all symbols and abbreviations used in figures. Common abbreviations, or those that have been defined in the text, need not be redefined in the figure legend.

Please also consider accessibility when designing each figure, so that all images can be easily understood by color-blind and visually impaired readers. Authors may review OUP’s guidelines for making figures accessible, which includes recommendations for color palettes, color contrast, image layout, and text accessibility. We also encourage authors to include alt text descriptions of their figures.

Raster images, such as photographs, paintings, or scans, can be provided as .tiff (preferred), .jpg, or .png files. This type of image should not include lettering. Resolution is measured by the number of dots or pixels per inch, referred to as dpi or ppi.

  • Minimum resolution required for color half-tones: 300dpi
  • Minimum resolution for grayscale half-tones: 600dpi
  • Minimum resolution for combination half-tones and line art: 600-900dpi
  • Minimum resolution for monochrome line art (complex or finely drawn): 1200dpi

Images of maps, charts, graphs, shapes, and diagrams are best rendered digitally as geometric forms called vector graphics. Vector images can be provided as .eps files; all fonts should be embedded.

Multi-panel figures should include all panels in a single figure file. Each panel should be labelled with a letter (A, B, C, D, etc.) in the upper-left corner of each panel. Labels should show up clearly against the background. The captions should be sufficiently detailed to comprehend each panel without extensive reliance on the main text.  

All figure axes must be labelled, including units where applicable. Any lettering should be at least 2mm in height in the final figure (after any resizing) and should be in proportion to the overall dimensions of the drawing. Line weight should not be less than 0.3pt at final size and solid lines are preferable. 

If any figure contains a map, the figure caption should include the source of the map or describe how the map was generated, and the text should include any geopolitical considerations.

Please ensure you have permission to re-use or adapt any third-party image materials. Figures not meeting these requirements may result in papers being sent back for further work.   

Figure accessibility and alt text

Incorporating alt text (alternative text) when submitting your paper helps to foster inclusivity and accessibility. Good alt text ensures that individuals with visual impairments or those using screen readers can comprehend the content and context of your figures. The aim of alt text is to provide concise and informative descriptions of your figure so that all readers have access to the same level of information and understanding, and that all can engage with and benefit from the visual elements integral to scholarly content. Including alt text demonstrates a commitment to accessibility and enhances the overall impact and reach of your work. 

Alt-text is applicable to all images, figures, illustrations, photographs.

Alt-text is only accessible via e-reader and so it won’t appear as part of the typeset article.

Detailed guidance on how to draft and submit alt text.

References

The journal follows OUP AMA 11 for reference formatting. The Journal follows the AMA reference style with a numerical citation system.

Authors should check all references carefully, list them at the end of the main text, and ensure that all references are cited in the text. Authors are responsible for the accuracy of reference information and may be queried to provide any missing reference elements during proofing. The references should be numbered in order of appearance in the text (in parentheses) and must be listed numerically in the reference list.  

Please additionally consider the following when formatting references:

  • References should include only articles cited in the text and should be listed in order of citation, including any listed in tables where the tables are first cited in the text.
  • Authors’ surnames and initials (the names of all authors should be given unless there are more than 6, in which case the names of the first 3 authors are used, followed by “et al”).
  • Abbreviate journal names according to the listing in the National Center for Biotechnology Information (NCBI) NLM Catalog database: https://www.ncbi.nlm.nih.gov/nlmcatalog/journals
  • DOIs must be included when applicable. Below please find some common AMA citation formats:

Articles

Journal Name [using NLM abbreviations]. Year;vol(issue): inclusive-pages. DOI (if available)

Books

Author A, Author BC. Book Title in Italics. Xth ed. Publisher; Year.

Chapters

Author AB. Article title in sentence case style. In: Editor CD, Editor EF, eds. Book Title in Italics. Xth ed. Publisher; Year: inclusive-pages.

Websites

Authors’ surnames and initials. Title. Website. [Date published]. Updated [date]. Accessed [date]. URL.

Supplementary material

Any supplementary data or material should be submitted at the same time as the main manuscript. Supplementary material should enhance the content but should not be necessary in order to understand the paper.  

Style and formatting of supplementary material should be consistent with that of the manuscript. Supplementary material will not be copyedited or typeset, and it will be available online upon publication.  

Any supplementary items should be submitted as clearly named files that are separate from the main manuscript file(s).  

Please see the Journal’s submission site for information regarding file requirements, such as file types and sizes.  

Any supplementary material will be published on OUP’s website alongside the article and must not be hosted elsewhere (e.g. the author’s personal or institutional website, Google Docs, YouTube), as links may expire.  

Supplementary material is subject to the same policy on changes to published papers as the main paper. 

Peer review process

The Journal operates double-anonymized peer review, meaning that the identity of the authors is hidden from reviewers, and the reviewers’ identities are hidden from the authors. The editors know the identity of both the reviewers and the authors.

During peer review, reviewers communicate directly with the editors but not the authors or other reviewers.

Once a submitted manuscript passes initial assessment by the Journal’s Editor-in-Chief, it will then be passed to a handling editor, who will oversee peer review and recommend a final decision. The Editor-in-Chief makes the final decision on the submitted manuscript.

Editors and reviewers must not handle manuscripts if they have a conflict of interest with an author or the content. Editors make every effort to avoid potential conflicts of interest in the assignment of other editors and peer reviewers. For more information, please see the section on Disclosure of potential conflicts of interest. During the peer review phase, your manuscript is typically sent to two (2) reviewers.

The Journal will not consider author-suggested reviewers.

If your manuscript is accepted for publication, no information about the review process or editorial decision process is published, unless one of the authors has a role on the journal. See the Disclosure of potential conflicts of interest section for more information in that case.

For full details about the peer review process, see Fair editing and peer review. 

Screening for misconduct

Manuscripts will be screened using iThenticate and Similarity Check to help detect publication misconduct including plagiarism and redundant publication.

The Journal uses ScholarOne’s Unusual Activity Detection tool to build confidence in the identity of authors and reviewers.

Manuscripts may also be screened using third party services to help detect integrity issues such as inappropriate image alteration and papermill activity.

Appeals and complaints

Authors may appeal an editorial decision. To do so, please contact the editorial office, providing as much specific detail as possible about why the original decision should be reconsidered. Every appeal will receive a response within a reasonable timeframe. Please do not resubmit your manuscript in the interim.

To register a complaint regarding non-editorial decisions, the Journal’s policies and procedures, editors, or staff, please contact us. Complaints will be taken seriously and will be carried forward following COPE guidelines and processes and/or sanctions will be enacted if deemed appropriate.

Publication and research ethics

Authorship

Authorship is limited to those who have made a significant contribution to the design and execution of the work described. Any contributors whose participation does not meet the criteria for authorship should be acknowledged but not listed as an author. For a detailed definition of authorship, please see the International Committee of Medical Journal Editors (ICMJE) definitions of authors and contributors.

The Journal does not allow ghost authorship, where an unnamed author prepares the article with no credit, or guest/gift authorship, where an author who made little or no contribution is listed as an author. The Journal follows Committee on Publication Ethics (COPE) guidance on investigating and resolving these cases. For more information, please see the OUP Publication Ethics page.

Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists. The use of AI (for example, to help generate content, write code, process data, or for translation) should be disclosed both in cover letters to editors and in the Methods or Acknowledgments section of manuscripts. Please see the COPE position statement on Authorship and AI for more details. Please consult the Policy on AI Use & Disclosure for OUP Journals Authors for detailed guidance, and see the disclosure of AI use section for more information.

Corresponding and submitting authors

The submitting and corresponding authors may be the same person or different people. The submitting author is responsible for submitting the manuscript and communicating with the Journal during the peer review process. Corresponding author duties include:

  • Signing the publishing agreement
  • Arranging payment for any charges due
  • Communicating after the paper has been accepted during the production process
  • Answering queries about the paper after publication

You must designate a corresponding author in the submission system and in the author list of the manuscript (refer to the Preparing your manuscript instructions).

The submitting author may choose to assign a different person as corresponding author on the “Authors & Institutions” page in the submission system.

If you would like to access Read and Publish funding to publish open access, the corresponding author designated in the submission system must have the qualifying institution as their primary affiliation.

After submission, changing who is designated as the corresponding author will be permitted only where there is a substantive reason to do so. We will not accept changes to the corresponding author to access Read and Publish funding.

For more information on Read and Publish funding, refer to the Open access charges section.

The corresponding author’s details in the submission system will also be used to judge eligibility for any member discounts.

Authorship changes

After manuscript submission, no authorship changes (including the authorship list, author order, and who is designated as the corresponding author) should be made unless there is a substantive reason to do so. The editor and all co-authors must agree on the change(s), and neither the Journal nor the publisher mediates authorship disputes. If individuals cannot agree on the authorship of a submitted manuscript, contact the editorial office. The dispute must be resolved among the individuals and their institution(s) before the manuscript can be accepted for publication. If an authorship dispute or change arises after a paper is accepted, contact OUP’s Author Support team: [email protected]. COPE provides guidance for authors on resolving authorship disputes.

ORCID

Submitting authors are required to provide an ORCID iD (Open Researcher and Contributor iD) at submission. If you do not already have an ORCID iD, you can register for free via the ORCID website.

As ORCID identifiers are collected, they are displayed in both the online and PDF versions of the publication, in compliance with recommended practice issued by ORCID.

ORCID functionality online allows users to link to the ORCID website to view an author’s profile and list of publications. ORCID iDs are displayed on web pages and are sent downstream to third parties in data feeds, where supported.

If you have registered with ORCID, you can associate your ORCID iD with your submission system account by going to your account details, entering your ORCID iD, and validating your details. Learn more about ORCID and how to link it to your account.

CRediT

The Journal uses the contributor roles taxonomy (CRediT), which allows authors to describe the contributor roles in a standardized, transparent, and accurate way. Authors should choose from the contributor roles outlined on the CRediT website and supply this information upon submission. You may choose multiple contributor roles per author. Any other individuals who do not meet the authorship criteria and made less substantive contributions should be listed in your manuscript as non-author contributors with their contributions clearly described. Following manuscript submission, any changes to contributor roles require the approval of the editor.

Group authorship

Groups (also known as corporate, organization, or collective names) who meet authorship criteria should be included in the main author list. Every individual in the group should fully meet the criteria for authorship. At least one individual must be designated on behalf of the group as the primary point of contact during the peer review and production processes, as well as for correspondence following publication. You may list this individual separately in the main author list if desired. A complete list of the individual members of the group must be included in the manuscript under Acknowledgments.

The group name will be entered for a PMC citation. The names of the individual members of the group will be entered as collaborator names for PMC citation, in the order in which they are published in the paper. If an individual is named both in the main author list and as a member of the group, they will appear in PMC as both an author and a collaborator.

Disclosure of AI use

OUP provides guidance on the responsible use of generative artificial intelligence (Gen AI) and AI-assisted technologies in developing content for publication in our journals. Authors must follow the central Policy on AI Use & Disclosure for OUP Journals Authors.

Disclosure of potential conflicts of interest

Authors

The Journal requires all authors to disclose any potential conflict of interest at the point of submission. It is the responsibility of the corresponding author to ensure that conflicts of interest of all authors are declared to the Journal.

A conflict of interest exists when the position, activities, or relationships of an individual, whether direct or indirect, financial or non-financial, could influence or be seen to influence the opinions or activities of the individual. For more information, refer to our definition of conflict of interest.

The Journal follows the COPE guidance for any suspected undisclosed conflict of interest before and after publication.

Conflicts of interest should be included as a clearly labeled section with the heading “Conflicts of interest” and placed on the title page. If there are no interests to disclose, this section should state “none declared”.

Peer reviewers

Individuals that have a conflict of interest relating to a submitted manuscript should recuse themselves and will not be assigned to oversee, handle, or peer review the manuscript.

If during peer review an editor, reviewer, or author becomes aware of a conflict of interest that was not previously known or disclosed they must inform the Editor-in-Chief immediately. 

Editors and editorial board members

At initial submission, the corresponding author must declare if the Editor-in-Chief, an editor, or an editorial board member of the Journal is an author of or contributor to the manuscript. Another editor without a conflict of interest will oversee the peer review and decision-making process. If accepted, a statement will be published in the paper describing how the manuscript was handled. The statement will read “[Author name] holds the position of [role] for American Journal of Clinical Pathology and has not peer reviewed or made any editorial decisions for this paper."

Previously published material

You should only submit your manuscript(s) to the Journal if:

  • It is original work by you and your co-author(s).
  • It is not under consideration, in peer review, or accepted for publication in any other publication.
  • It has not been published in any other publication.
  • It contains nothing abusive, defamatory, derogatory, obscene, fraudulent, or illegal.

The submitting author must disclose in their cover letter and provide copies of all related or similar preprints, dissertations, manuscripts, published papers, and reports by the same authors (i.e., those containing substantially similar content or using the same, similar, or a subset of data) that have been previously published or posted electronically or are under consideration elsewhere at the time of manuscript submission. You must also provide a concise explanation of how the submitted manuscript differs from these related manuscripts and papers. All related previously published papers should be cited as references and described in the submitted manuscript.

The Journal does not discourage you from presenting your findings at conferences or scientific meetings but recommends that you refrain from distributing complete copies of your manuscripts, which might later be published elsewhere without your knowledge.

For previously published materials including tables and figures, please see the Reusing copyrighted materials section.

Preprints

As an author, you retain the right to make an Author’s Original Version (preprint) available through various channels and this does not prevent submission to the Journal. If accepted, you are required to update the status of any preprint, including adding a published paper’s DOI. For full details on allowed channels and updating your preprint, please see our Author self-archiving policy.

Reusing copyrighted material 

As an author, you must obtain permission for any material used within your manuscript for which you are not the rightsholder, including quotations, tables, figures, images, data, or software. In seeking permissions for published materials, first contact the publisher rather than the author. For unpublished materials, start by contacting the creator. Copies of each grant of permission should be provided to the editorial office of the Journal. The permissions agreement must include the following: 

  • Nonexclusive rights to reproduce the material in your paper in American Journal of Clinical Pathology 
  • Rights for use in print and electronic format at a minimum, and preferably for use in any form or medium 
  • Lifetime rights to use the material 
  • Worldwide English-language rights 

If you have chosen to publish under an open access license but have not obtained open access re-use permissions for third-party material contained within the manuscript, this must be stated clearly by supplying a credit line alongside the material with the following information: 

  • Title of content 
  • Author, Original publication, year of original publication, by permission of [rightsholder] 
  • This image/content is not covered by the terms of the Creative Commons license of this publication. For permission to reuse, please contact the rights holder.  

Our publisher, Oxford University Press, provides detailed Copyright and Permissions Guidelines, and a summary of the fundamental information. 

Misconduct

Authors should observe high standards with respect to research integrity and publication ethics as set out by the Committee on Publication Ethics (COPE). Falsification or fabrication of data including inappropriate image manipulation, plagiarism, including duplicate publication of the author's own work without proper citation, and misappropriation of work are all unacceptable practices. Allegations of ethical misconduct, both directly and through social media, are treated seriously and will be investigated in accordance with the relevant COPE guidance.

If misconduct has been established beyond reasonable doubt, this may result in one or more of the following outcomes, among others:

  • If a submitted manuscript is still under consideration, it may be rejected and returned to the author.
  • If a paper has already been published online, depending on the nature and severity of the infraction, either a correction notice will be published and linked to the paper, or retraction of the paper will occur, following the COPE Retraction Guidelines.
  • The relevant party’s institution(s) and/or other journals may be informed.

Manuscripts submitted to the Journal may be screened with plagiarism-detection software. Any manuscript may be screened, especially if there is reason to suppose that part or all the of the manuscript has been previously published.

COPE defines plagiarism as:

“when somebody presents the work of others (data, words or theories) as if they were their own and without proper acknowledgment.”

COPE defines redundant/overlapping publication as:

“when a published work (or substantial sections from a published work) is/are published more than once (in the same or another language) without adequate acknowledgment of the source/cross-referencing/justification,

or

when the same (or substantially overlapping) data is presented in more than one publication without adequate cross-referencing/justification, particularly when this is done in such a way that reviewers/readers are unlikely to realize that most or all the findings have been published before.”

COPE defines citation manipulation as:

“behaviors intended to inflate citation counts for personal gain, such as: excessive self-citation of an authors’ own work, excessive citation to the journal publishing the citing article, and excessive citation between journals in a coordinated manner.”

Data fabrication is defined as intentionally creating fake data or misrepresenting research results. An example includes making up data sets.

Data falsification is defined as manipulating research data with the purpose of intentionally giving a false representation. This can apply to images, research materials, equipment, or processes. Examples include cropping of gels/images to change context and omission of selected data.

If notified of a potential breach of research misconduct or publication ethics, the Journal editor and editorial office staff may inform OUP and/or the author’s institutional affiliation(s). Authors should be prepared to provide additional information on request.

Ethical research 

The Journal follows Committee on Publication Ethics (COPE) guidelines on ethical oversight. We take research integrity seriously, and all research published in the Journal must have been conducted in a fair and ethical manner. Wherever appropriate, the Journal requires that all research be done according to international and local guidelines.  

Human participants

When reporting on human participants, you should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration, which were developed by the World Medical Association. For non-interventional studies, where ethical approval is not required or where a study has been granted an exemption by an ethics committee, this should be stated within the manuscript with a full explanation. Otherwise, manuscripts must include a statement in the Methods section that the research was performed after approval by a local ethics committee, institutional review board and/or local licensing committee, or that such approval was not required. The name of the authorizing body and any reference/permit numbers (where available) should also be stated there. Please be prepared to provide further information to the editorial office upon request.

Human participants must give written informed consent, or if they are minors or incapacitated, such consent must be obtained from their parents or guardians. Consent forms should cover not only study participation but also the publication of the data collected and deposition in databases and/or biobanks. Also, any patient or provider information should be anonymized to the extent possible; names and ID numbers should not be used in the text and must be removed from any images (X-rays, photographs, etc.). Please note blanking out an individual’s eyes in a photograph is not an effective way to conceal their identity. In studies where verbal, rather than written, informed consent was obtained, this must be explained and stated within the manuscript. If informed consent is not required or where a study has been granted an exemption, this must be included in the Methods section along with the name of the authorizing body. The Journal does not routinely collect consent forms, but authors should be prepared to provide written consent forms signed by the participants or other appropriate documentation to the editorial office upon request. For further guidance and examples, please refer to COPE’s guidance on consent.

Clinical trials

Clinical trials should be registered before enrollment of the first participant in accordance with the criteria outlined by the International Committee of Medical Journal Editors (ICMJE). When reporting primary or secondary analyses from a clinical trial, follow these criteria:

  • Provide the trial registration number at the end of the Abstract.
  • When the trial acronym is first used in the manuscript, provide the registration number and a link to the trial registration, which should be cited as a reference.
  • If your data have been deposited in a public repository and/or are being used in a secondary analysis, please state at the end of the Abstract the unique, persistent data set identifier, and repository name and number.
  • When submitting the manuscript, you must disclose any protocol alterations and all posting of results of the submitted work or closely related work in registries.

Where available, registration numbers should be provided not only for the trial you are reporting but also for any other trial mentioned in the manuscript. When the trial acronym is first used in the manuscript, provide the registration number and a link to the trial registration, which should be cited as a reference. 

Animals

Studies involving animals require approval from the relevant institutional ethics committee or institutional animal use and care committee, and the research must be conducted in accordance with applicable national and international guidelines. All such manuscripts must include a statement in the Methods section providing details of the name of the committee(s) that approved the study, as well as the permit or animal license numbers where available. Where a study has been granted an exemption, this must be stated in the Methods section along with the name of the authorizing body. Please be prepared to provide further information to the editorial office upon request.

Geopolitical considerations

The Journal remains neutral with regards to geopolitical issues.  

When including maps, you should include information on how the map was generated or sourced, and the text should also include any geopolitical considerations.  

Maps should be meaningful, informative, and accurate in the context of the research. You may consider including a statement of geopolitical neutrality.

All territorial descriptions, maps, and author affiliations are provided by you; therefore, they do not necessarily represent the views of the editorial team, American Society for Clinical Pathology, or OUP.

C4DISC partnership

The Journal, American Society for Clinical Pathology, and OUP aim to create a community that fosters diversity, equity, and inclusion. As part of our commitment to these principles, OUP is a proud partner of the Coalition for Diversity & Inclusion in Scholarly Communications (C4DISC). C4DISC works with organizations and individuals within the scholarly communications landscape to foster equity, inclusion, diversity, and accessibility across the publishing industry and its published outputs.

The Journal is proud to adopt the Joint Statement of Principles of C4DISC.

Inclusive language and images

As defined by the Linguistic Society of America:

“Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities”.

We encourage you to consider using inclusive language and images when preparing your manuscript. For guidelines, please see the “Correct and Preferred Usage" chapter of the 11th edition of the AMA Manual of Style.

Accessibility

Written, visual, and audio content in your submission should be accessible to all. Please see the C4DISC guidelines for making text, images, charts, tables, and audio and video accessible.

Availability of Data and Materials 

Where ethically feasible, American Journal of Clinical Pathology strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files or deposited in a public repository whenever possible. Information on general repositories for all data types, and a list of recommended repositories by subject area, is available here.

Data and Software Citation 

The American Journal of Clinical Pathology supports the Force 11 Data Citation Principles and requires that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI). Data citations should include the minimum information recommended by DataCite:  

[dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier 

*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list. 

Software citations should include the minimum information recommended by the FORCE11 Software Citation Implementation Group: 

Author/Developer, Release date, Title, Publisher (repository or archive name), Identifier 

If there is an article describing the software, it is recommended to cite both the software and the article.  

Data availability statement

The inclusion of a data availability statement is a requirement for papers published in the Journal. Data availability statements provide a standardized format for readers to understand the availability of original and third-party data underlying the research results described in the paper. The statement should describe and provide means of access, where possible, by linking to the data or providing the required unique identifier.

More information and example data availability statements.

Choosing where to archive your data

Authors are highly encouraged to select a repository that issues DOIs as this helps to facilitate persistent linking to the dataset from the research article. You may refer to online resources such as FAIRsharing.org and re3data.org for lists of data repositories, including information on certification status and services offered.

We suggest you consider these options when choosing your repository:

Digital preservation

Content published in the Journal will automatically be deposited into digital preservation services, including CLOCKSS, the Global LOCKSS Network, and Portico. This ensures the long-term preservation of your work. Through LOCKSS, participating institutions can sustain access to content if the Journal were to otherwise be unavailable, even for a short period of time. Should the Journal ever cease to publish, or content would otherwise become permanently unavailable, long-term access to the archives of CLOCKSS and Portico would be triggered. Until such a trigger event were to occur, this content is not available to the public through CLOCKSS and Portico.

Self-archiving

Self-archiving refers to posting a copy of your work on a publicly accessible website or repository. Under certain circumstances, you may self-archive versions of your work on your own webpages, on institutional webpages, and in other repositories. For information about the Journal's policy, and to learn which version(s) of your paper are acceptable for self-archiving, please see our Author self-archiving policy.

Publishing agreement and charges

Authors, please read each section on the publishing agreement and charges carefully.

If you have any questions relating to your publishing agreement or charges, please contact OUP SciPris support.

After your manuscript is accepted, you will be asked to sign a license to publish through our licencing and payment portal, SciPris. The Journal offers the option of publishing under either a non-open access (standard) license or an open access (Creative Commons) license. There is a charge to publish under an open access license, which allows your paper to be freely accessible to all readers immediately upon online publication. Editorial decisions occur prior to this step and are not influenced by payment or ability to pay. The standard license makes your paper available only to Journal subscribers and there is no license charge. This license grants OUP an exclusive license to publish and distribute the content. There is no transfer of ownership of the copyright. You, the author, retain copyright for the content.

Papers can be published under the following:

Please see our guidance on Licenses, copyright, and re-use rights for more information regarding these publishing agreement options.

Complying with funder mandates

Please note that some funders require open access publication as a condition of funding. If you are unsure whether you are required to publish open access, please clarify any such requirements with your funder or institution before selecting your license.

Further information on funder mandates and direct links to a range of funder policies.

Charges

Open access charges

Please see the details of open access licenses and charges. If you select an open access license, then you must pay the open access charge or request to use an institutional agreement to pay the open access charge through our licensing and payment portal, SciPris.

OUP has a growing number of open access agreements with institutions and consortia, which provide funding for open access publishing (also known as Read and Publish agreements). This means corresponding authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution has an open access agreement.

To be eligible for one of OUP’s Read and Publish agreements, the corresponding author must provide their qualifying institution as their primary affiliation when they submit their manuscript. After submission, changing the corresponding author in order to access Read and Publish funding is not permissible.

Member discounts

Corresponding authors who are members of American Society for Clinical Pathology may be eligible for discounts on publication charges. Please provide the member identifier when prompted as you submit your manuscript.

Open access charge discount: Please see the open access charge list.

Changes to published papers

The Journal will only make changes to published papers if the publication record is seriously affected by the academic accuracy of the published information. Changes to a published paper will be accompanied by a formal correction notice linking to and from the original paper.

As needed, we follow the COPE guidelines on retractions.

For more information and details of how to request changes, including for authors who wish to update their name and/or pronouns, please see OUP’s policy on changes to published papers.

Promoting your work

As the author, you are the best advocate for your work, and we encourage you to be involved in promoting your publication. Sharing your ideas and news about your publication with your colleagues and friends could take as little as 15 minutes and will make a real difference in raising the profile of your research.

You can promote your work by:

  • Sharing your paper with colleagues and friends. If your paper is published open access, it will always be freely available to all readers, and you can share it without any limitations. Otherwise, use the toll-free link that is emailed to you after publication. It provides permanent, free access to your paper, even if your paper is updated.
  • Signing up for an ORCID iD author identifier to distinguish yourself from any other researchers with the same name, create an online profile showcasing all your publications, and increase the visibility of your work.
  • Using social media to promote your work. To learn more about self-promotion on social media, see our social media guide for authors.

Find out how OUP promotes your content. 

Press releases

If you would like to arrange an embargo date so that a press release can be issued simultaneously with the publication of your paper, please contact us as soon as possible. Once published, the paper cannot be temporarily withdrawn. If your paper has already been accepted, contact [email protected]. If your manuscript is still under review, please contact the editorial office ([email protected]).

Contact us

For questions regarding submission and review, including appeals, you can reach the editorial office by email at [email protected].

After your paper has been sent to production, you can contact [email protected] for questions regarding publishing agreements and charges, the production process, or publication. Please see Changes to published papers if you need to request a substantive change to your published paper.

To register a complaint regarding non-editorial decisions, the Journal’s policies and procedures, editors, or staff, please contact Sara Yanny-Tillar, Director of Scientific Publications at ASCP. Complaints will be taken seriously and will be carried forward following COPE guidelines and processes.

For changes that arise after acceptance but before publication that cannot be addressed in the proof process (including changes to the author list), contact the Author Support Team at [email protected].

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period